- Home
- WHWK vs GALT Comparison
WHWK vs GALT Comparison
Compare WHWK & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WHWK | GALT |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | United States |
| Employees | 22 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.8M | 199.2M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | WHWK | GALT |
|---|---|---|
| Price | $3.39 | $2.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.00 | ★ $8.50 |
| AVG Volume (30 Days) | 180.7K | ★ 340.4K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.39 | $1.22 |
| 52 Week High | $4.40 | $7.13 |
Technical Indicators
Market Signals| Indicator | WHWK | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 46.33 | 37.18 |
| Support Level | $1.84 | $2.07 |
| Resistance Level | $3.79 | $3.32 |
| Average True Range (ATR) | 0.24 | 0.21 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 33.58 | 13.69 |
Price Performance
Historical ComparisonAbout WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.